The November 2011 issue of the Investor Advisory Service is now available. Subscribers may log in at http://www.investoradvisoryservice.com/Subscribers.aspx to access the issue.
Are you attending the American Association of Individual Investors's Investor Conference in Las Vegas this November 2011? If so, you can hear Investor Advisory Service Editor-in-Chief Doug Gerlach present a workshop on the formula that IAS analysts use to pick winning stocks for the newsletter.
In the November 2010 issue of the Investor Advisory Service we recommended Bio-Reference Laboratories, an operator of medical testing facilities. This small company had revenues in 2009 of $362.7 million, and had grown earnings per share at an annualized rate of 23.6% since 2001. How have the company and its stock performed in the year since it was recommended?
How much is good advice worth to you as an investor?
How much would you pay for independent, unbiased recommendations for your stock portfolio? Advice that is free from the conflicts of interest that are rife on Wall Street. Advice that doesn't come from some anonymous Internet chat board or some blustery talking head on television. Advice that's racked up a record of outperforming the overall market, as well as nearly every other stock newsletter, over the past 15 years.
As we reminded Investor Advisory Service subscribers in the September 2011 issue, it has been a rough few weeks for investors. Is now the time to buy U.S. stocks?
In the October 2010 issue of the Investor Advisory Service we recommended DG FastChannel, Inc., a Texas-based provider of digital technology services that enable the electronic delivery of ads, syndicated programs and news video to broadcasters and other media outlets. This small company had revenues in 2009 of $190.9 million, and had grown earnings per share at an annualized rate of 36.9% since 2000. How have the company and its stock performed in the year since it was recommended?
In the September 2010 issue of the Investor Advisory Service we recommended Perrigo Company, a Michigan-based maker of store-brand medicines. This midsized company had revenues in 2010 of $2.3 billion, and had grown earnings per share at an annualized rate of 17.2% since 2001. How have the company and its stock performed in the year since it was recommended?
The Hulbert Financial Digest recently published an update on the long-term performance of the investment newsletters that it covers, and the results for the Investor Advisory Service newsletter are superior!
In each issue of the Investor Advisory Service, our analysts recommend three stocks for subscribers. In addition, we provide updates on companies previously-recommended by the Service, with news of recent results and several tables of information about all stocks currently being tracked. One of the items in the tables is a column labeled "Buy." But does this really mean a subscriber should buy that stock?